Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.

Br J Haematol · 2020 · PMC8221029 · PMID 32410281

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Particularly in MDS patients, there may be significant differences between clinical trial populations and patients in routine clinical care and registries, as the median age at diagnosis of MDS patients is around 76 years. 55 Additionally, specific outcomes may be more important for a specific patient subgroup.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.